Skip to main content

Table 2 Mild cognitive impairment participant overview

From: Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

  Total MCI sMCI cMCI
Urine    
 Participants 209 167 42
 Male/female 95/114 80/87 15/27
 Mean age (SD) 76.33 (6.03) 76.17 (5.60) 76.91 (7.38)
 MMSE 26.86 (2.75) 26.93 (2.94) 26.55 (1.76)
 CDR 0.49 (0.08) 0.48 (0.09) 0.51 (0.08)
 Reported SSRI medication 16 12 4
Serum    
 Participants 165 90 75
 Male/female 71/94 42/48 29/46
 Mean age 77.50 (6.49) 75.98 (5.95) 79.32 (6.67)
 MMSE 26.73 (2.24) 26.81 (2.38) 26.63 (2.07)
 CDR 0.49 (0.11) 0.48 (0.10) 0.53 (0.12)
 Reported SSRI medication 11 8 3
  1. Overview of the two MCI subgroups used in the study. All samples in the study were taken at baseline; however, one MCI subgroup remained stable throughout follow-up visits (sMCI), whilst the second converted to a clinical diagnosis of AD at subsequent follow-up visits (cMCI). SSRI selective serotonin reuptake inhibitor, MMSE Mini-Mental State Examination score, CDR Clinical Dementia Rating